Table 3.
Subgroup | No. of Deaths |
HR | 95% CI | P | Interaction |
|||
---|---|---|---|---|---|---|---|---|
Chemotherapy | Observation | HR | 95% CI | P | ||||
OS | 0.71 | 0.43 to 1.17 | .18 | |||||
ACN/PAP | 60 of 131 | 50 of 116 | 1.00 | 0.68 to 1.47 | .99 | |||
MIP/SOL | 64 of 141 | 89 of 164 | 0.71 | 0.51 to 0.99 | .04 | |||
Test of heterogeneity across trials | .27* | |||||||
.16† | ||||||||
.18‡ | ||||||||
DFS | 0.54 | 0.34 to 0.86 | .009 | |||||
ACN/PAP | 75 of 131 | 59 of 116 | 1.11 | 0.78 to 1.57 | .57 | |||
MIP/SOL | 70 of 141 | 109 of 164 | 0.60 | 0.44 to 0.82 | .001 | |||
Test of heterogeneity across trials | .10* | |||||||
.07† | ||||||||
.05‡ | ||||||||
SDFS | ||||||||
ACN/PAP | 68 of 131 | 53 of 116 | 1.12 | 0.77 to 1.61 | .56 | 0.53 | 0.32 to 0.86 | .01 |
MIP/SOL | 62 of 141 | 101 of 164 | 0.59 | 0.42 to 0.81 | .001 | |||
Test of heterogeneity across trials | .26* | |||||||
.04† | ||||||||
.06‡ |
NOTE. Similar results were observed when using TNM stage instead of T and N of TNM in multivariable Cox regression model (data not shown).
Abbreviations: ACN, acinar; DFS, disease-free survival; HR, hazard ratio; MIP, micropapillary; OS, overall survival; PAP, papillary; SDFS, specific disease-free survival; SOL, solid.
Test evaluating homogeneity of treatment effect across trials in ACN/PAP group.
Test evaluating homogeneity of treatment effect across trials in MIP/SOL group.
Test evaluating joint hypotheses of * and †.